The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Current State of Breast Cancer Diagnosis, Treatment, and Theranostics
Open accessAbstract
Breast cancer is one of the leading causes of cancer-related morbidity and mortality in women worldwide. Early diagnosis and effective treatment of all types of cancers are crucial for a positive prognosis. Patients with small tumor sizes at the time of their diagnosis have a significantly higher survival rate and a significantly reduced probability of the cancer being fatal. Therefore, many novel technologies are being developed for early detection of primary tumors, as well as distant metastases and recurrent disease, for effective breast cancer management. Theranostics has emerged as a new paradigm for the simultaneous diagnosis, imaging, and treatment of cancers. It has the potential to provide timely and improved patient care via personalized therapy. In nanotheranostics, cell-specific targeting moieties, imaging agents, and therapeutic agents can be embedded within a single formulation for effective treatment. In this review, we will highlight the different diagnosis techniques and treatment strategies for breast cancer management and explore recent advances in breast cancer theranostics. Our main focus will be to summarize recent trends and technologies in breast cancer diagnosis and treatment as reported in recent research papers and patents and discuss future perspectives for effective breast cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement
Siu, A. L., & on behalf of the U.S. Preventive Services Task Force (2016) · Annals of Internal Medicine · doi:10.7326/m15-2886 · Cited by 2,094
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874
A Deep Learning Mammography-based Model for Improved Breast Cancer Risk Prediction
Yala, A., Lehman, C., Schuster, T., Portnoi, T., & Barzilay, R. (2019) · Radiology · doi:10.1148/radiol.2019182716 · Cited by 758
Liu, R., Xiao, W., Hu, C., Xie, R., & Gao, H. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.005 · Cited by 250 · cited 1×
“On subcutaneous injection of the NPs in tumor-bearing Balb/c mice, these particles displayed size-reducible properties as a result of the presence of hyaluronidase leading to highly homogenous intra-tumor distribution of the NPs [205,206].”
BackgroundEfficacy of PI3K inhibitors in advanced breast cancer
Verret, B., Cortes, J., Bachelot, T., Andre, F., & Arnedos, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz381 · Cited by 221
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Xu, H., Yu, S., Liu, Q., Yuan, X., Mani, S., Pestell, R. G., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0467-2 · Cited by 168
Shapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1777 · Cited by 152
Bartelink, I. H., Jones, E. F., Shahidi‐Latham, S. K., Lee, P. R. E., Zheng, Y., Vicini, P., van ‘t Veer, L., Wolf, D., Iagaru, A., Kroetz, D. L., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1211 · Cited by 96
Cited by
Magnetic Resonance Imaging and Iron-oxide Nanoparticles in the era of Personalized Medicine
Rahman, M. (2023) · Nanotheranostics · doi:10.7150/ntno.86467 · Cited by 244
Targeting Breast Cancer: An Overlook on Current Strategies
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88
Fariha, F. T. J., Fuad, M., Saha, C. S., Hossen, S., & Hossain, M. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-13315-6 · Cited by 1
Metadata
- Authors
- Bhushan, A., Gonsalves, A., & Menon, J. U.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-05-14
- Volume
- 13
- Issue
- 5
- Pages
- 723
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W3162543922
- Cited by
- 298
- References
- 11
- FWCI
- 11.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
